Multicenter phase 2-3 trial of neurocognition impact of hippocampal avoidance during prophylactic cranial irradiation for small cell lung cancer
Dr. Vinai Gondi
The randomized phase 2-3 NRG-CC003 trial in the US and Canada evaluated hippocampal avoidance during prophylactic cranial irradiation in patients with small cell lung cancer. Addition of hippocampal avoidance during prophylactic cranial irradiation reduced the risk of overall neurocognitive toxicity (p=0.039), with noninferior risk of intracranial relapse (p<0.0001), similar survival (p=0.33), and similar grade ≥3 toxicity (p=0.88).
